Navigation Links
Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
Date:9/16/2010

SAN FRANCISCO, Sept. 16 /PRNewswire/ -- In response to recent press coverage concerning investment to support the development of a biobusiness park in Minnesota, Burrill & Company would like to clarify that investment discussions are still ongoing.

"We have been in active discussions for several months with one potential investor who has an interest in the project," said G. Steven Burrill, CEO, Burrill & Company. "However, contrary to the impressions conveyed in the press coverage, no decisions have yet been made and there can be no guarantees about the actual outcome at this point.

"We do have a strong interest in the State of Minnesota and independent of our continuing efforts at Elk Run, we have been actively investing in the State, creating jobs and establishing an innovative biotech venture capital community," Burrill added. "We have already established an office in Minnesota and are actively investing in promising start-up companies. Bringing more than $100 million into the State in the last year is evidence of our significant ongoing commitment to Minnesota, independent of the potential fund commitment."

Burrill & Company investments in Minnesota:

- Invested $8M in Nora Therapeutics, developer of women's reproductive health drugs and devices. Burrill's investment also brought an additional $17M into the company, as part of a syndicate with Prospect Venture Partners and Vivo Ventures.

- In 2009, Burrill & Company invested $5M in Segetis, a start-up company developing chemicals made from biomass. The total investment into the company was over $17M, with additional syndicate member Khosla Ventures. Segetis is located in Golden Valley, MN.

- This year, one of Burrill & Company's portfolio companies, GEVO, acquired a corn-based ethanol plant owned and operated by Agri-Energy in Luverne, MN. The transaction, worth over $20M, will bring the latest isobutanol technology into the State as well as generate dozens of new jobs.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report (www.burrillreport.com) and annual "State of the Industry" report, the latest of which has just been released entitled Biotech 2010-Life Sciences: Adapting for Success.


'/>"/>
SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shawn Cross Joins Burrill Merchant Banking
2. Burrill & Company Invests in Taiwan Liposome Company
3. Joao Paulo Baptista Joins Burrill & Company
4. CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th
5. Burrill & Company and WR Hambrecht + Co to Collaborate on OpenIPO(R) Transactions
6. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
7. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
8. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
9. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
10. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
11. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... be held February 8-9, 2016, at the Waldorf Astoria ... & Healthcare Conference, taking place in New ... James Sapirstein , Chief Executive Officer of ContraVir, will ...
(Date:2/4/2016)... , February 4, 2016 Strasbourg, ... (ABL), Inc. --> Strasbourg, France , ... --> PharmaVentures is pleased to announce that it acted ... biopharmaceutical manufacturing unit in Strasbourg, France , ... --> --> Transgene (Euronext: TNG), ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
Breaking Biology Technology:
(Date:2/4/2016)... -- The field of Human Microbiome research and ... hubs of the biotechnology industry. While the Human ... human microbiota, have garnered a lot of attention ... has literally exploded in terms of both basic ... on biomedical aspects of research, development, and commercial ...
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
Breaking Biology News(10 mins):